Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.

ETF Trends • Jul 13, 2026

Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH.

GlobeNewsWire • Jul 2, 2026

Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.

Zacks Investment Research • Jun 29, 2026

Healthcare stocks have become a haven for investors ditching tech

Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.

Market Watch • Jun 26, 2026

Biotech ETF Index Surges 10% After Rebalance

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.

ETF Trends • Jun 25, 2026

AbbVie's $11 Billion Immunology Bet

In this week's edition of InnovationRx, we look at AbbVie's new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more. To get it in your inbox, subscribe here.

Forbes • Jun 24, 2026

Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apogee Therapeutics, Inc. (NasdaqGM: APGE) to AbbVie (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Apogee will receive $135.11 in cash for each share of Apogee that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa.

Business Wire • Jun 24, 2026

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apogee Therapeutics, Inc. (NASDAQ: APGE)

NEW YORK, June 22, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Apogee Therapeutics, Inc. (NASDAQ: APGE ) related to its sale to AbbVie Inc. Under the terms of the proposed transaction, Apogee shareholders are expected to receive $135.11 per share in cash.

PRNewsWire • Jun 22, 2026

APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apogee Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Apogee Therapeutics, Inc. (NASDAQ: APGE) to AbbVie for $135.11 per share in cash.Halper Sadeh encourages Apogee shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation concerns whether Apogee and its board of directors violated the fede.

Business Wire • Jun 22, 2026

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

AbbVie ​will acquire ‌biotech ​Apogee ​Therapeutics for $10.9 ⁠billion ​in ​cash, they said ​on ​Monday, as ‌the ⁠company builds its ​next-generation ​immunology ⁠pipeline.

Reuters • Jun 22, 2026